

Level 14, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

> Phone 64-4-460-4990 Fax 64-4-460-4995

www.pharmac.govt.nz

Please note – a word document of this document (rather than a PDF) is available from <u>Jessica@pharmac.govt.nz</u> upon request.

Schedule 4: Proposal form

You should expand the boxes as necessary.

[Supplier to insert date]

Stephen Woodruffe Therapeutic Group Manager PHARMAC PO Box 10-254 (or for courier delivery: Level 14, Cigna House 40 Mercer Street) Wellington New Zealand

By facsimile (04) 460 4995

By email: stephen.woodruffe@pharmac.govt.nz

Dear Stephen

Proposal for the supply of quinapril and/or quinapril with hydrochlorothiazide

In response to your request for proposals (**RFP**) dated **18 June 2008**, we put forward the following proposal in respect of [*insert pharmaceutical(s)*].

Set out below is further information in support of our proposal.

(a) Our contact details:

Name of supplier	
Contact person	
Address	
Phone	
Facsimile	
Email address	

(b) Details of pharmaceutical presentation:

Chemical name Investing in Health

Strength (e.g. 5mg)	
Form (e.g. tablet)	
Brand name	
Pack size (e.g. 30's)	
Packaging type (e.g. blister)	

(c) Key features of our proposal:

(d) Information relating to pricing (\$NZ, GST exclusive), including any related conditions or proposed terms affecting cost for PHARMAC:

(e) Evidence of market approval and any other required consents:

Date of market approval (please attach copy of Medsafe Gazette notice)	
OR Date of submission of dossier (please attach confirmation from Medsafe that dossier has been submitted)	
OR Expected date of dossier submission to Medsafe	
Insert any other consents required for pharmaceutical	

(f) Information about our ability to ensure the continuity of supply of the pharmaceutical:

(g) Information about our previous supply performance and relevant expertise:

(h) Proposals/suggestions regarding the pharmaceutical not expressly identified in this RFP that we would like PHARMAC to consider as part of our proposal:

(i) Reasons why PHARMAC should accept our proposal:

(j) Additional information that PHARMAC should consider when evaluating our proposal:

(k) Samples of the pharmaceuticals included in this proposal have been forwarded to PHARMAC (delete as appropriate): Yes/No